Global Atypical antipsychotic drugs Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2026

MarketResearch.biz delivers in-depth insights on the global atypical antipsychotic drugs market in its upcoming report titled, “Global Atypical antipsychotic drugs Market Trends, Applications, Analysis, Growth, and Forecast: 2017 to 2026”. The global atypical antipsychotic drugs market is estimated to register a CAGR of X.X% in terms of value during forecast period 2017–2026. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2026. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global atypical antipsychotic drugs market report has been segmented on the basis of drug class, indication, distribution channel, and region.

This report is based on synthesis, analysis, and interpretation of information gathered regarding the target market from various sources. Our analysts have analyzed the information and data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the market. In addition, an in-house study has been made of the global economic conditions and other economic indicators and factors to assess their respective impact on the market historically, as well as the current impact in order to make informed forecasts about the scenarios in future.

Atypical antipsychotic drugs are a type of antipsychotic drugs used in treatment of psychosis. Atypical antipsychotic drugs do not cure psychosis but help in controlling symptoms such as hallucinations, paranoia, hearing voices, and delusions, among others. Atypical antipsychotics produce a sedative or tranquilizing effect. Some of the atypical antipsychotic drugs are also used for severe anxiety, persistent hiccups, problems with balance, and nausea. It can also be given in agitation and some psychotic experiences in dementia. Atypical antipsychotic drugs are primarily prescribed in forms of tablets and liquids, and are available in a wide variety of dosages.

High prevalence of psychosis and related disorders coupled with increasing incidence of various disorders such as schizophrenia and dementia are major factors driving adoption of atypical antipsychotic drugs which in turn is boosting growth of the global atypical antipsychotic drugs market. In addition, advancements in drugs and increasing availability of specialized drugs for treatment of psychosis are other major factors anticipated to fuel growth of the global atypical antipsychotic drugs market over the forecast period.

However, high costs associated with procurement and use of these drugs, especially in developing economies is a major factor restraining growth of the global atypical antipsychotic drugs market. Additionally, high investments required for R&D of atypical antipsychotic drugs, side effects related with consumption of these drugs, and lack of awareness about atypical antipsychotic drugs in emerging economies are other major factors expected to hamper growth of the global atypical antipsychotic drugs market over the forecast period.

Currently, the market in North America dominates the global atypical antipsychotic drugs market in revenue terms owing to high awareness about psychotic disorders, presence of proper healthcare infrastructure, and easy availability of atypical antipsychotic drugs in countries in the region. The market in Europe accounted for second-highest revenue share in the global atypical antipsychotic drugs market, due to high healthcare expenditure by governments of countries, and high disposable income, followed by markets in Asia Pacific, Latin America, and Middle East & Africa respectively. The market in Asia Pacific is projected to witness fastest growth in terms of revenue, owing to presence of a large patient pool, increasing incidence of schizophrenia and bipolar disorders, and rise in government initiatives for improvement of healthcare facilities in the region.

Global atypical antipsychotic drugs market segmentation:

By drug class:

• Risperidone
• Olanzapine
• Quetiapine
• Ziprasidone
• Aripiprazole
• Paliperidone
• Lurasidone

By indication:

• Bipolar I Disorder
• Schizophrenia
• Schizoaffective Disorder
• Major Depressive Disorder (MDD)

By distribution channel:

• Hospital Pharmacy
• Retail Pharmacy
• Drug Store
• E-commerce

By region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• GlaxoSmithKline Plc.
• Johnson and Johnson
• Pfizer Inc.
• Eil Lilly and Company
• Bristol-Myers Squibb Company
• Allergan Plc.
• Cardinal Health Inc.
• Sanis Health Inc.
• Sun Pharmaceutical Industries Ltd.
• Novartis AG